GlassScriptPhysician profile
Arsenio M Cachero
NPI 1225483514
$4,495.11
in general payments reported to CMS, 2019-2025
30 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $727 · 2022: $1,069 · 2023: $999 · 2024: $563 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $549.15 | 2021-2024 | Andexxa, Lokelma |
| Novo Nordisk INC | $403.59 | 2023-2025 | Wegovy, Ozempic |
| Teva Pharmaceuticals USA, INC. | $248.74 | 2022-2023 | Austedo |
| Glaxosmithkline, LLC. | $234.72 | 2024-2025 | Arexvy |
| Medtronic, INC. | $222.98 | 2024-2025 | Corevalve Evolut R, Closurefast |
| Lilly USA, LLC | $215.14 | 2022-2025 | Mounjaro |
| Abbott Laboratories | $197.61 | 2022-2023 | Freestyle Libre 3 |
| Nevro Corp. | $158.27 | 2023 | Senza |
| Zimmer Biomet Holdings, INC. | $150.00 | 2021 | |
| Heartflow, INC. | $150.00 | 2025 | |
| Zoll Respicardia, INC. | $148.16 | 2021 | |
| Abiomed | $142.15 | 2025 | |
| Neurocrine Biosciences, INC. | $139.33 | 2022 | |
| Recordati_rare_diseases_inc. | $132.89 | 2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.89 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $124.79 | 2023 | Auvelity |
| Biosense Webster, INC. | $121.53 | 2025 | Qdot Micro |
| Alkermes, INC. | $112.38 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $110.01 | 2022 | |
| Corcept Therapeutics | $109.99 | 2023 | Korlym |
| Amgen INC. | $100.77 | 2021 | |
| Aurinia Pharma U.S., INC. | $98.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.91 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.85 | 2022 | |
| Silk Road Medical, INC. | $79.70 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Scynexis, INC. | $77.87 | 2022 | |
| W. L. Gore & Associates, INC. | $61.67 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Pfizer INC. | $40.24 | 2025 | |
| Boston Scientific Corporation | $31.90 | 2023-2025 | Lithovue |
| Smith+Nephew, INC. | $21.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arsenio Cachero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.